Kevin McCulloch, President and Chief Operating Officer of Xeris Biopharma Holdings, Inc., filed a Form 4 on November 6, 2026, disclosing the sale of 25,000 shares of common stock on November 5, 2026, pursuant to a Rule 10b5-1 trading plan.
Key Highlights
- Transaction date: McCulloch disposed of 25,000 shares of Xeris Biopharma Holdings common stock on November 5, 2026.
- Weighted average price: Shares were sold at a weighted average price of $12.4886, with individual transactions ranging from $12.380 to $12.510, inclusive.
- Post-transaction direct ownership: Following the sale, McCulloch directly beneficially owns 1,559,208 shares of common stock.
- Indirect holdings: An additional 25,000 shares are held indirectly by McCulloch's spouse; he disclaims beneficial ownership of those shares except to the extent of his pecuniary interest.
- 10b5-1 plan: The sale was made pursuant to a Rule 10b5-1 trading plan adopted by McCulloch on September 4, 2025.
- Transaction code: The disposal is coded "S" (open-market sale) in Table I of the filing.
McCulloch's November 2026 Scheduled Sale Under Rule 10b5-1 Plan
According to the Form 4 filed with the SEC on November 6, 2026, Kevin McCulloch, identified in the filing as President and Chief Operating Officer of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), sold 25,000 shares of the company's common stock on November 5, 2026. The filing states the transaction was effected pursuant to a Rule 10b5-1 trading plan that McCulloch adopted on September 4, 2025.
The filing reports a weighted average sale price of $12.4886 per share. The shares were sold across multiple transactions at prices ranging from $12.380 to $12.510, inclusive. The filing notes that McCulloch "undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."
Following the reported transaction, McCulloch directly beneficially owns 1,559,208 shares. The filing also discloses 25,000 shares held indirectly through his spouse. McCulloch disclaims beneficial ownership of those indirectly held shares, the filing states, "except to the extent of his pecuniary interest therein," and the inclusion of those shares "shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose." The Form 4 was signed by Beth Hecht as attorney-in-fact on November 6, 2026.
What Was Disclosed
The filing disclosed a disposition of 25,000 Xeris Biopharma Holdings common shares by the company's President and COO on November 5, 2026, at a weighted average price of $12.4886, executed under a pre-established Rule 10b5-1 plan adopted September 4, 2025.




Please wait processing your request...